Which mechanism of action explains how hydrochlorothiazide increases urine output
US Pharm. 2008;33(6):HS10-HS18. Show Heart failure (HF) afflicts 5.3 million people in the United States, with 550,000 new cases each year. 1,2 The current treatment of HF consists of ACE inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, digoxin, and diuretics. Because of decreased cardiac output, patients with HF have increased activity of the sympathetic nervous system and renin-angiotensin aldosterone system (RAAS), along with an increase in nonosmotic vasopressin release. Combined, this leads to diminished renal sodium and water excretion, as well as edema and symptoms of volume overload.3 Diuretics have been used in the treatment of patients with HF since 1919, with the discovery of the diuretic trait of mercury.4 Currently, loop diuretics, thiazide diuretics, and aldosterone antagonists are commonly used in patients with HF to remove excess volume and relieve symptoms. Epidemiology Etiology and Clinical Presentation The cardinal manifestations of HF vary depending on whether right ventricular (RV) or LV failure is present. Although both types may occur together, the symptoms of one side often predominate. Systemic edema including ascites, increased jugular venous pressures, hepatosplenomegaly, peripheral edema, and anasarca are mainly associated with RV failure (cor pulmonale). Dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and nocturia, all of which are related to pulmonary congestion symptoms, are associated with LV failure.8 The approach first developed by the New York Heart Association (NYHA) to quantify clinical assessment of HF remains widely utilized and is described in TABLE 1.9 Loop Diuretics: Loop diuretics remain the mainstay therapy for fluid removal in patients with HF. They exert their action by inhibiting the sodium-potassium-chloride cotransport system located within the thick ascending limb of the loop of Henle. Patients with chronic HF tend to have a decreased response to normal doses of loop diuretics secondary to reduced renal blood flow, increased sodium reabsorption at sites downstream (distal tubule and collecting duct) due to the activation of RAAS and the sympathetic nervous system, and possible delayed intestinal absorption.11 The four loop diuretics used in the treatment of HF are furosemide, bumetanide, torsemide, and ethacrynic acid (TABLE 2). Ethacrynic acid is rarely used, but is reserved for patients with true type-1 hypersensitivity reaction to sulfa drugs. There are minimal clinically significant differences between furosemide, bumetanide, and torsemide.11 One issue with furosemide is that its bioavailability is 11% to 90% with erratic oral absorption; thus, patients who do not respond to oral furosemide might benefit from switching to bumetanide or torsemide. 10 Murray et al illustrated with an open-label, randomized trial in 234 patients with chronic HF that patients who are treated with torsemide have less fatigue and lower rate of readmission by 52% for HF at one year compared to those treated with furosemide.12 Intravenous diuretics are more potent than their equivalent oral doses, especially with severe or decompensated HF due to significant interstitial edema of the gastrointestinal tract. It is suggested that continuous infusion of loop diuretics has potential advantages over intermittent bolus diuretic administration in patients with severe HF, such as preventing postdiuretic sodium-chloride retention, in addition to being more efficient and having less potential for toxicity.13,14 The most common adverse effects associated with loop diuretics include skin rashes, interstitial nephritis, ototoxicity, gout, metabolic alkalosis, volume depletion, hypokalemia, hypomagnesemia, hyperuricemia, and azotemia.10 Thiazide Diuretics: Thiazide diuretics inhibit sodium reabsorption by blocking the electroneutral sodium-chloride cotransporter at the distal tubule. Because the cotransporter only reabsorbs about 5% of filtered sodium, thiazide diuretics are less efficacious than loop diuretics in producing diuresis or natriuresis. The four thiazide diuretics utilized in the U.S. (chlorthalidone, chlorothiazide, hydrochlorothiazide, and metolazone) are described in TABLE 2. These agents possess very similar characteristics except for chlorothiazide, which may be administered IV.10 Thiazide diuretics are usually added to a loop diuretic regimen to augment the diuresis in patients with refractory edema. This combination appears to be synergistic by possible multiple mechanisms including decreased postdiuretic sodium chloride retention, decreased sodium transport along the proximal tubule through inhibition of carbonic anhydrase, and by inhibition of sodium reabsorption at the distal convoluted tubule.15,16 The effective doses of thiazide diuretics vary among patients, with some patients requiring daily administration and others only requiring them once weekly. Another approach is to use the combination for a short, fixed period of time and then revert to monotherapy with a loop diuretic when the patient achieves euvolemia. The most common adverse effects associated with the thiazide diuretics include skin rashes, interstitial nephritis, pancreatitis, gout, alkalosis, volume depletion, hypokalemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia in diabetics, and azotemia.10 Aldosterone Antagonists: Although aldosterone antagonists are not technically classified as diuretics, their adjunctive use in HF relates to their additive diuretic effect in combination with other drugs, decreasing the cardiac workload and reducing edema. Patients with HF have increased RAAS activity, and the direct local effect of aldosterone on the heart may include hypertrophy, fibrosis, and proarrhythmia.17,18 There are currently two aldosterone antagonists available in the U.S.--spironolactone and eplerenone (TABLE 2). The Randomized Aldactone Evaluation Study (RALES) evaluated spironolactone, which competes with aldosterone for the mineralocorticoid receptor sites in the distal renal tubules, increasing sodium chloride and water excretion while conserving potassium and hydrogen ions. The clinical trial showed that the addition of spironolactone to patients with systolic dysfunction and NYHA class III resulted in a 30% reduction in mortality and a 35% reduction in hospitalization for HF; nevertheless, patients treated with spironolactone had a significant reduction in systolic and diastolic blood pressure and a lower incidence of hypokalemia, but a dose-related increased risk of hyperkalemia. 19 However, due to nonselective binding of spironolactone to the androgen and progesterone receptors, endocrine adverse effects such as gynecomastia, breast pain, menstrual irregularities, impotence, and decreased libido were experienced. Eplerenone, a more selective agent to the mineralocorticoid receptor, has fewer endocrine adverse effects than spironolactone. Eplerenone was evaluated in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which enrolled patients who had myocardial infarction and reduced LV systolic function (LV ejection fraction [LVEF] ?40%). Patients who were treated with eplerenone had significant reduction in all causes of mortality, which was entirely due to the reduction in cardiovascular mortality.20 The use of an aldosterone antagonist requires very careful monitoring for renal function and potassium, as the incidence of fetal hyperkalemia has increased since the RALES publication.21 Special consideration should be taken in patients with other comorbidities such as significant renal dysfunction, advanced age, and diabetes. Investigational Agents A recent multicenter, randomized, double-blind study evaluated oral tolvaptan, a selective V2 receptor antagonist, in patients with HF and systolic dysfunction. In this study there was no difference between tolvaptan and placebo on the LV volume, but there was a reduction in the combined end point of mortality and HF in the patients who were treated with tolvaptan.25 Conivaptan, an agent that blocks both V1a and V2, is currently FDA approved for the treatment of hyponatremia. It was evaluated in a small study in patients with advanced HF. A single IV dose of conivaptan resulted in significant reduction in the preload and an increase in urine output compared to placebo. 26 Large trials are needed to evaluate vasopressin antagonists in HF, which have a potential benefit in inducing aquaresis without an increase in the activation of RAAS.27 Adenosine Antagonists:Adenosine reduces renal blood flow and decreases the glomerular filtration rate (GFR) in patients with HF.28 Four adenosine receptors (ARs) have been identified: A1, A2A, A2B , and A3.29 According to Elkayam et al, direct infusion of adenosine into the renal arteries of patients with chronic HF leads to reduction of renal blood flow.30 This mechanism suggests that blocking the ARs in the kidneys may enhance the renal blood flow in patients with chronic HF. Gottlieb et al showed in small group of patients with HF that administering an A1 antagonist resulted in increased sodium excretion without a decrease in GFR compared to furosemide.31 Givertz et al evaluated the effects of the A1 antagonist KW-3902 in patients with acute decompensated HF and renal impairment or diuretic resistance.32 The infusion of KW-3902 resulted in increased urine output and decreased serum creatinine compared to placebo. These few studies showed promising results, but safety needs to be established in humans because ARs are found in all organs and play a key role in regulating metabolism. Larger studies are under way (PROTECT-1 and PROTECT-2) to evaluate the potential use of this new class of medication in patients with HF. Conclusion
REFERENCES To comment on this article, contact . Which mechanism of action explains how hydrochlorothiazide?Mechanism of action
Hydrochlorothiazide belongs to the thiazide class of diuretics. It reduces blood volume by acting on the kidneys to reduce sodium (Na+) reabsorption in the distal convoluted tubule.
How does hydrochlorothiazide produce diuresis?Hydrochlorothiazide is in a class of medications called diuretics ('water pills'). It works by causing the kidneys to get rid of unneeded water and salt from the body into the urine.
What is the mechanism of action for diuretic?They act by diminishing sodium reabsorption at different sites in the nephron, thereby increasing urinary sodium and water losses. A second class of diuretics, sometimes termed aquaretics, instead inhibit water reabsorption by blocking vasopressin receptors along the connecting tubule and collecting duct.
What is the mechanism of action of thiazide like diuretics?The MOA of thiazide diuretics is to decrease sodium reabsorption and therefore decreased fluid reabsorption; this directly causes decreased levels of circulating sodium.
|